Capricorn Fund Managers’s ResMed RMD Stock Holding History

Capricorn Fund Managers’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-230,947	Closed	-$34.2M	–	82
2023 Q3	$34.2M	Buy	230,947 +169,722	+277%	+$30.7M	11.85%	1
2023 Q2	$13.4M	Buy	+61,225	New	+$13.6M	4.8%	7
2022 Q3	–	Sell	-95,879	Closed	-$20.1M	–	112
2022 Q2	$20.1M	Buy	+95,879	New	+$20.4M	3.65%	6
2022 Q1	–	Sell	-22,445	Closed	-$5.85M	–	111
2021 Q4	$5.85M	Buy	+22,445	New	+$5.82M	1.64%	15

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capricorn Fund Managers's RMD Position: Q4 2023 in Review

Capricorn Fund Managers sold out of ResMed (RMD) in Q4 2023, closing a stake of 230,947 shares — an estimated $34.2M sold.

Capricorn Fund Managers first reported a position in RMD in Q4 2021 and held it in 4 quarters. The position peaked at $34.2M in Q3 2023. 688 funds tracked by Wall St. Rank hold RMD as of Q4 2023.

Capricorn Fund Managers reported no remaining ResMed position as of Q4 2023 after selling out during the quarter.
Capricorn Fund Managers sold 230,947 ResMed shares in Q4 2023, an estimated $34.2M.
Capricorn Fund Managers first reported a position in ResMed in Q4 2021 and held it in 4 quarters.
Capricorn Fund Managers's ResMed position peaked at $34.2M in Q3 2023.
688 funds tracked by Wall St. Rank held ResMed as of Q4 2023.

Based on Capricorn Fund Managers's 13F filing for Q4 2023, filed 10 Jan 2024.